Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

Tetratherix Hits the ASX: What Investors Need to Know About This Fresh Life Sciences Listing

Tetratherix Limited (ASX: TTX) officially began trading on the Australian Securities Exchange following a successful initial public offering that raised A$25 million through the issuance of 8.68 million shares at A$2.88 each. The float places the company’s market capitalisation at approximately A$145 million. Importantly, the capital raised leaves Tetratherix with an estimated cash balance of…

ByUjjwal MaheshwariJuly 1, 2025

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

It's been a tough few years for ASX biotech small caps. Even in the last 18 months, the market recovered from post-COVID inflation small cap biotechs have been left behind. The ASX 200 Healthcare Index is down 7% in 2025 whilst the broader ASX 200 is up 4% (yes, even with the crash due to…

ByNick SundichJuly 1, 2025

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical "risk off" moves professional investors usually make when faced with uncertainty. But what exactly does "risk off" mean and how relevant is it for retail investors? Should you be risk off too or should you ride out geopolitical uncertainty? Few would've predicted Israel would've…

ByNick SundichJune 18, 2025

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

In the decade since fertility provider Monash IVF (ASX:MVF) listed, it was not an easy journey. Only a few months ago, we thought the business had turned a corner and many others did too. Then...trouble struck. Is this a buy the dip opportunity, or a risk of catching a falling knife? Introduction to Monash IVF Monash…

ByNick SundichJune 10, 2025

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the Australian market. Before this year is over, the company anticipates launching another 2 tests - PromarkerEndo and PromarkerEso; and is eyeing off the US market too. Recap of Proteomics (ASX:PIQ) For investors that are new to…

ByNick SundichMay 28, 2025

This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true

'The investor who says, "This time is different," when in fact it’s virtually a repeat of an earlier situation, has uttered among the four most costly words in the annals of investing'. This quote was said by John Templeton’s in his work '16 rules for Investment Success'. Why Templeton thought 'This Time is Different' was…

ByNick SundichMay 21, 2025

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is expecting to complete its Phase 3 trials during FY26 (the 12 months starting on July 1, 2025), and success here would lead to unlocking of market opportunities worth a cumulative US$9.1bn. Specifically, the global DFI…

ByNick SundichMay 6, 2025

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he built it into a US$1tn+ empire owning many of America's best companies and profiting off them. But of course, all good things must come to an end - at least a tenure led by the…

ByNick SundichMay 5, 2025

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this morning! The company already had licensing deals with 2 companies for other jurisdictions, but not for the US (or China) which were and are larger opportunities. But this morning, it unveiled the deal to shareholders…

ByNick SundichMay 1, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Tetratherix Hits the ASX: What Investors Need to Know About This Fresh Life Sciences Listing

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

How to stop the ASX decline? ASIC and investors have some radical ideas

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here